Scarica l'app Stockscreener
1.36
3.55%
-0.05
Dopo l'orario di chiusura:
1.35
-0.01
-0.74%
NanoViricides Inc Borsa (NNVC) Ultime notizie
NanoViricides Receives DRC Approval to Advance Phase II Ebola Trial for Oral Antiviral NV-387 - citybuzz -
As the Ebola Epidemic Spreads, NV-387 Oral Gummies Can Enter a Phase II Clinical Trial for Treatment of EbolaNanoViricides Proposal is Approved by the Pillar Committee in DR Congo - ACCESS Newswire
NNVC Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts Investor SentimentEarnings Expansion Phase - newsline.com
As the Ebola Emergency Outbreak Grows Rapidly, NanoViricides Has Proposed a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatmentwith Superior Oral Administration and Escape Resistance Features Over Antibodies - ACCESS Newswire
NanoViricides pushes chewable Ebola drug trial as Congo outbreak escalates - Stock Titan
NanoViricides Files for $50 Million Mixed Shelf Offering - Moomoo
NNVC stock up 17% today: What’s driving the rally? - MSN
NanoViricides (NNVC) Edges Lower Within Narrow Trading RangePre-Earnings Momentum - newsline.com
NanoViricides (NNVC) Slides 3.6% as Selling Pressure IntensifiesInstitutional Buy Signals - The Legal Advocate
NanoViricides (NNVC) Retreats 4.3%, Nears Critical Support at $1.69AAII Bullish - thelegaladvocate.com
Ebola Global Health Emergency Needs a Broad-Spectrum DrugNV-387 is a Strong Potential Candidate, Says NanoViricides - ACCESS Newswire
NNVC Q1 2026 Earnings: EPS Surpasses Expectations Amid Ongoing Development EffortsEPS Surprise History - newsline.com
NNVC Stock Price, Quote & Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
Measles Rare Pediatric Disease Drug Designation Application Filed for NV-387, PRV Provides for Strong Business Case, Says NanoViricides - ACCESS Newswire
Nanoviricides(NNVC) Stock Options Chain | Quotes & News - Moomoo
NanoViricides (NNVC) Surges 15.9% as Speculative Buying Drives Shares Above $1.75MA Cross Alert - The Legal Advocate
NanoViricides (NNVC) Surges 13.6% as Stock Approaches Key ResistanceSwing Trade Setups - The Legal Advocate
NNVC Stock Gains Attention As NV-387 Targets Ebola And Measles - StocksToTrade
NNVC Stock Draws Traders As NV-387 Targets Ebola, Measles - timothysykes.com
In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides - ACCESS Newswire
Contact | Statesman-Examiner - FinancialContent
Rare Ebola strain has no treatment; NanoViricides lines up oral NV-387 - Stock Titan
NanoViricides Inc. (NNVC) Q1 2026 Earnings: Narrower Loss Drives Positive Stock ReactionProfit Guidance Range - newsline.com
Shelton biotech NanoViricides raises $2M in stock offering - Hartford Business Journal
A. G. P. Maintains Nanoviricides(NNVC.US) With Buy Rating, Maintains Target Price $6 - Moomoo
NanoViricides Highlights NV-387 Strategy for Ebola Outbreak - TipRanks
NanoViricides Completes $2 Million Registered Direct Offering - TipRanks
NanoViricides Raises $2 Million in Registered Direct Offering With Common and Pre-Funded Warrants - TradingView
Market movers: Amer Sports, Tiziana Life Sciences, Ideal Power, NanoViricides... - Proactive financial news
NanoViricides Raises $2 Million in Registered Direct Offering to Advance Broad-Spectrum Antiviral Drug - citybuzz -
NanoViricides closes $2M direct offering - Yahoo! Finance Canada
NanoViricides, Inc - Reuters
NanoViricides Announces Closing of ~$2 Million Registered Direct Offering - PharmiWeb.com
Antiviral developer NanoViricides secures $2M from single institutional investor - Stock Titan
NanoViricides Highlights Broad-Spectrum Antiviral Candidate Amid Ebola Outbreak - citybuzz -
NNVC Stock Up 17% Today: What’s Driving The Rally? - Stocktwits
Ebola outbreak renews focus on broad-spectrum antivirals - EMJ
NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak - Yahoo! Finance Canada
New Ebola strain has no treatment — NanoViricides highlights oral NV-387 - Stock Titan
NanoViricides Prices $2 Million Registered Direct Offering - citybuzz -
NanoViricides Advances NV-387 Toward Phase II Trials for MPox in DRC, Expands Orphan Drug Strategy - citybuzz -
NanoViricides to raise $2M in registered direct offering - Yahoo! Finance Canada
NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering - ACCESS Newswire
Clinical-stage antiviral firm NanoViricides prices $2M stock-and-warrant deal - Stock Titan
NanoViricides, Inc. Has Filed its Quarterly ReportNV-387 Advancing for Phase II - Lelezard
Broad antiviral NV-387 drug candidate targets measles, mpox, smallpox - Stock Titan
NANOVIRICIDES, INC. 3Q FY2026: Net loss $(1.99M), EPS $(0.09) — 10-Q Summary - TradingView
NanoViricides: Fiscal Q3 Earnings Snapshot - marketscreener.com
NanoViricides, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2026 - marketscreener.com
NNVC Stock Chart | NANOVIRICIDES INC (NYSEARCA:NNVC) - ChartMill
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):